Helen Dickens, Chief Support Officer at Breast Cancer Now, said:
“Today’s announcement of an increase to the cost-effectiveness threshold for medicines is a welcome step that could see more people getting access to vital life-extending treatments. For too long, cost-effectiveness thresholds have jeopardised the approval of some groundbreaking new medicines.
“We’ve been urgently calling for people living with incurable secondary breast cancer to get access to the drugs they so desperately need and deserve. These changes must translate to increased access to new medicines for people living with this disease.”
ENDS
Notes to editors
These reported changes would apply to NICE decisions made in England, and Wales and Northern Ireland adopt those decisions.